UCB Management

Management Kriterienprüfungen 4/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Jean-Christophe Tellier

Geschäftsführender

€5.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	21.2%
Amtszeit als Geschäftsführer	8.3yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	5.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	9yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Jean-Christophe Tellier im Vergleich zu den Einnahmen von UCB verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2022	€6m	€1m	€420m
Jun 30 2022	n/a	n/a	€887m
Mar 31 2022	n/a	n/a	€971m
Dec 31 2021	€6m	€1m	€1b
Sep 30 2021	n/a	n/a	€996m
Jun 30 2021	n/a	n/a	€936m
Mar 31 2021	n/a	n/a	€834m
Dec 31 2020	€7m	€1m	€732m
Jun 30 2020	n/a	n/a	€743m
Mar 31 2020	n/a	n/a	€767m
Dec 31 2019	€87k	n/a	€790m
Jun 30 2019	n/a	n/a	€652m
Mar 31 2019	n/a	n/a	€722m
Dec 31 2018	€76k	n/a	€792m
Jun 30 2018	n/a	n/a	€872m
Mar 31 2018	n/a	n/a	€812m
Dec 31 2017	€76k	n/a	€752m
Sep 30 2017	n/a	n/a	€708m
Jun 30 2017	n/a	n/a	€664m
Mar 31 2017	n/a	n/a	€604m
Dec 31 2016	€5m	€987k	€543m

Vergütung im Vergleich zum Markt: Jean-ChristopheDie Gesamtvergütung ($USD6.41M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt MX ($USD5.73M).

Entschädigung vs. Einkommen: Jean-ChristopheDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Jean-Christophe Tellier (63 yo)

8.3yrs

Amtszeit

€5,808,530

Vergütung

Mr. Jean-Christophe Tellier has been the Chief Executive Officer and Executive Director of UCB SA since January 1, 2015 and April 24, 2014 respectively and also was an Interim Chief Financial Officer since...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jean-Christophe Tellier	CEO & Executive Director	8.3yrs	€5.81m	keine Daten
Sandrine Dufour	Executive VP & CFO & Chief Corporate Development	2.8yrs	keine Daten	keine Daten
Kirsten Lund-Jurgensen	Executive Vice President of Supply & Technology Solutions	3.6yrs	keine Daten	keine Daten
Dhavalkumar Patel	Executive VP & Chief Scientific Officer	5.5yrs	keine Daten	keine Daten
Jean-Luc Fleurial	Executive VP & Chief Human Resources Officer	3.2yrs	keine Daten	keine Daten
Iris Low-Friedrich	Executive VP	15.1yrs	keine Daten	keine Daten
Emmanuel Caeymaex	Executive VP of Immunology Solutions & Head of US	8.2yrs	keine Daten	keine Daten
Charl van Zyl	Executive VP of Neurology Solutions & Head of EU/International	3.6yrs	keine Daten	keine Daten
Caroline Vancoillie	Chief Accounting Officer	10.1yrs	keine Daten	keine Daten
Antje Witte	Head of Investor Relations	13.3yrs	keine Daten	keine Daten
Denelle J. Johnson	Executive VP & General Counsel	no data	keine Daten	keine Daten
Gwendoline Ornigg	Head of Global Communication	no data	keine Daten	keine Daten

5.5yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrenes Management: UCB NDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.5 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jean-Christophe Tellier	CEO & Executive Director	9yrs	€5.81m	keine Daten
Gerhard Mayr	Honorary Chairman	no data	€70.00k	keine Daten
Mark Eyskens	Honorary Chairman	18.3yrs	€15.50k	keine Daten
Daniel Janssen	Honorary Deputy Chairman	no data	€28.50k	keine Daten
Albrecht De Graeve	Director	13yrs	€86.00k	keine Daten
Georges Jacobs Hagen	Honorary Chairman	no data	€30.00k	keine Daten
Diégo du de Bergendal	Honorary Chairman	2yrs	€87.50k	keine Daten
Karel Boone	Honorary Chairman	no data	€49.00k	keine Daten
Jonathan Peacock	Independent Chair of the Board	2yrs	€157.17k	keine Daten
Charles-Antoine Emmanuel Janssen	Director	11yrs	€108.50k	keine Daten
Jonkheer van Rijckevorsel	Director	9yrs	€86.00k	keine Daten
Fiona du Monceau	Vice-Chair of the Board	2yrs	€159.83k	keine Daten

9.0yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: UCB NDie Vorstandsmitglieder gelten als erfahren (9 Jahre durchschnittliche Amtszeit).

UCB Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB SA, Annual General Meeting, Apr 27, 2023

UCB SA, Annual General Meeting, Apr 28, 2022

Recent updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

Investor sentiment deteriorated over the past week

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

Upcoming dividend of €0.91 per share

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

First half 2021 earnings released: EPS €3.00 (vs €1.92 in 1H 2020)

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

Independent Vice Chairman Pierre Gurdjian has left the company

Chairman Diégo du de Bergendal has left the company

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs

Full year 2020 earnings released: EPS €3.87 (vs €4.22 in FY 2019)

Revenue beats expectations

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter